FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313461963> ?p ?o ?g. }

• W4313461963 endingPage "e1003988" @default.
• W4313461963 startingPage "e1003988" @default.
• W4313461963 abstract "Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we performed a drug target Mendelian randomisation (MR) analysis to evaluate the association of genetically proxied inhibition of LDL-c-lowering drug targets on risk of PrCa.Single-nucleotide polymorphisms (SNPs) associated with LDL-c (P < 5 × 10-8) from the Global Lipids Genetics Consortium genome-wide association study (GWAS) (N = 1,320,016) and located in and around the HMGCR, NPC1L1, and PCSK9 genes were used to proxy the therapeutic inhibition of these targets. Summary-level data regarding the risk of total, advanced, and early-onset PrCa were obtained from the PRACTICAL consortium. Validation analyses were performed using genetic instruments from an LDL-c GWAS conducted on male UK Biobank participants of European ancestry (N = 201,678), as well as instruments selected based on liver-derived gene expression and circulation plasma levels of targets. We also investigated whether putative mediators may play a role in findings for traits previously implicated in PrCa risk (i.e., lipoprotein a (Lp(a)), body mass index (BMI), and testosterone). Applying two-sample MR using the inverse-variance weighted approach provided strong evidence supporting an effect of genetically proxied inhibition of PCSK9 (equivalent to a standard deviation (SD) reduction in LDL-c) on lower risk of total PrCa (odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.76 to 0.96, P = 9.15 × 10-3) and early-onset PrCa (OR = 0.70, 95% CI = 0.52 to 0.95, P = 0.023). Genetically proxied HMGCR inhibition provided a similar central effect estimate on PrCa risk, although with a wider 95% CI (OR = 0.83, 95% CI = 0.62 to 1.13, P = 0.244), whereas genetically proxied NPC1L1 inhibition had an effect on higher PrCa risk with a 95% CI that likewise included the null (OR = 1.34, 95% CI = 0.87 to 2.04, P = 0.180). Analyses using male-stratified instruments provided consistent results. Secondary MR analyses supported a genetically proxied effect of liver-specific PCSK9 expression (OR = 0.90 per SD reduction in PCSK9 expression, 95% CI = 0.86 to 0.95, P = 5.50 × 10-5) and circulating plasma levels of PCSK9 (OR = 0.93 per SD reduction in PCSK9 protein levels, 95% CI = 0.87 to 0.997, P = 0.04) on PrCa risk. Colocalization analyses identified strong evidence (posterior probability (PPA) = 81.3%) of a shared genetic variant (rs553741) between liver-derived PCSK9 expression and PrCa risk, whereas weak evidence was found for HMGCR (PPA = 0.33%) and NPC1L1 expression (PPA = 0.38%). Moreover, genetically proxied PCSK9 inhibition was strongly associated with Lp(a) levels (Beta = -0.08, 95% CI = -0.12 to -0.05, P = 1.00 × 10-5), but not BMI or testosterone, indicating a possible role for Lp(a) in the biological mechanism underlying the association between PCSK9 and PrCa. Notably, we emphasise that our estimates are based on a lifelong exposure that makes direct comparisons with trial results challenging.Our study supports a strong association between genetically proxied inhibition of PCSK9 and a lower risk of total and early-onset PrCa, potentially through an alternative mechanism other than the on-target effect on LDL-c. Further evidence from clinical studies is needed to confirm this finding as well as the putative mediatory role of Lp(a)." @default.
• W4313461963 created "2023-01-06" @default.
• W4313461963 creator A5008417296 @default.
• W4313461963 creator A5010921216 @default.
• W4313461963 creator A5013184354 @default.
• W4313461963 creator A5015814169 @default.
• W4313461963 creator A5036589831 @default.
• W4313461963 creator A5043339098 @default.
• W4313461963 creator A5054061856 @default.
• W4313461963 creator A5054105424 @default.
• W4313461963 date "2023-01-03" @default.
• W4313461963 modified "2023-10-09" @default.
• W4313461963 title "Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study" @default.
• W4313461963 cites W1252855759 @default.
• W4313461963 cites W1905058580 @default.
• W4313461963 cites W1966775465 @default.
• W4313461963 cites W1977915186 @default.
• W4313461963 cites W2001328643 @default.
• W4313461963 cites W2008790999 @default.
• W4313461963 cites W2039153962 @default.
• W4313461963 cites W2045337585 @default.
• W4313461963 cites W2073836327 @default.
• W4313461963 cites W2104549677 @default.
• W4313461963 cites W2104570606 @default.
• W4313461963 cites W2106036991 @default.
• W4313461963 cites W2112409006 @default.
• W4313461963 cites W2113699335 @default.
• W4313461963 cites W2147671638 @default.
• W4313461963 cites W2153118028 @default.
• W4313461963 cites W2153860431 @default.
• W4313461963 cites W2165144879 @default.
• W4313461963 cites W2166320441 @default.
• W4313461963 cites W2298141847 @default.
• W4313461963 cites W2324862792 @default.
• W4313461963 cites W2339488754 @default.
• W4313461963 cites W2508534964 @default.
• W4313461963 cites W2555614465 @default.
• W4313461963 cites W2557654447 @default.
• W4313461963 cites W2594300836 @default.
• W4313461963 cites W2596179513 @default.
• W4313461963 cites W2606910957 @default.
• W4313461963 cites W2613603864 @default.
• W4313461963 cites W2724719188 @default.
• W4313461963 cites W2761786170 @default.
• W4313461963 cites W2770246164 @default.
• W4313461963 cites W2777550987 @default.
• W4313461963 cites W2786371198 @default.
• W4313461963 cites W2806504012 @default.
• W4313461963 cites W2886173583 @default.
• W4313461963 cites W2890202245 @default.
• W4313461963 cites W2892371813 @default.
• W4313461963 cites W2895486342 @default.
• W4313461963 cites W2900569176 @default.
• W4313461963 cites W2901670341 @default.
• W4313461963 cites W2940327706 @default.
• W4313461963 cites W2952686929 @default.
• W4313461963 cites W2989670329 @default.
• W4313461963 cites W2995245946 @default.
• W4313461963 cites W3008748669 @default.
• W4313461963 cites W3011942165 @default.
• W4313461963 cites W3025634989 @default.
• W4313461963 cites W3033181610 @default.
• W4313461963 cites W3040746161 @default.
• W4313461963 cites W3080477490 @default.
• W4313461963 cites W3083496521 @default.
• W4313461963 cites W3093402173 @default.
• W4313461963 cites W3103804121 @default.
• W4313461963 cites W3117246007 @default.
• W4313461963 cites W3121173001 @default.
• W4313461963 cites W3128646645 @default.
• W4313461963 cites W3133859624 @default.
• W4313461963 cites W3134551291 @default.
• W4313461963 cites W3150450748 @default.
• W4313461963 cites W3161425918 @default.
• W4313461963 cites W3167602921 @default.
• W4313461963 cites W3173300899 @default.
• W4313461963 cites W3183508038 @default.
• W4313461963 cites W3191578671 @default.
• W4313461963 cites W3195291379 @default.
• W4313461963 cites W3204010869 @default.
• W4313461963 cites W3205644245 @default.
• W4313461963 cites W3210406414 @default.
• W4313461963 cites W3215894083 @default.
• W4313461963 cites W4210962061 @default.
• W4313461963 cites W4211103501 @default.
• W4313461963 cites W4220764353 @default.
• W4313461963 cites W4224299153 @default.
• W4313461963 cites W4225363012 @default.
• W4313461963 cites W4242238601 @default.
• W4313461963 cites W65262745 @default.
• W4313461963 cites W3202880306 @default.
• W4313461963 doi "https://doi.org/10.1371/journal.pmed.1003988" @default.
• W4313461963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36595504" @default.
• W4313461963 hasPublicationYear "2023" @default.
• W4313461963 type Work @default.
• W4313461963 citedByCount "3" @default.
• W4313461963 countsByYear W43134619632023 @default.
• W4313461963 crossrefType "journal-article" @default.

• next